Vor Biopharma Inc. (VOR) Key Metrics
VOR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $977.0M
- Enterprise value
- $682.7M
- P/E (TTM)
- 0.1
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.78
VOR key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVOR returns How much profit the business earns on the capital it uses.
VOR financial health Debt, liquidity and how easily interest is covered.
VOR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VOR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VOR cash returned to shareholders
VOR key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $13.08 | $22.20 | $45.00 | $133.00 | $232.40 | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | — | −94.5% | −58.7% | −39.5% | −52.1% | −155.0% | — | — |
| Return on invested capital (ROIC) | — | −223.2% | −183.6% | −171.5% | −243.2% | −356.9% | — | — |
| Return on assets (ROA) | −229.3% | −66.3% | −46.3% | −34.0% | −43.3% | −101.1% | −200.1% | −412.3% |
| Return on tangible assets | −150.0% | −81.8% | −56.2% | −30.8% | −28.4% | −57.1% | −110.3% | −412.3% |
| Financial health | ||||||||
| Total debt | $3.0M | $31.8M | $35.7M | $38.9M | $18.0M | $18.3M | — | $4.5M |
| Cash & short-term investments | $455.2M | $91.9M | $137.2M | $230.2M | $207.5M | $48.5M | $6.5M | $929,000 |
| Net debt | −$452.2M | −$60.1M | −$101.5M | −$191.3M | −$189.5M | −$30.2M | −$6.5M | $3.5M |
| Debt / equity | — | 0.33 | 0.24 | 0.16 | 0.08 | 0.38 | — | — |
| Debt / assets | 0.01 | 0.22 | 0.17 | 0.13 | 0.07 | 0.24 | — | 4.43 |
| Current ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Quick ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Interest coverage | — | — | — | -70.6 | -44.4 | — | -17.1 | -2.9 |
| Working capital | $432.9M | $77.9M | $125.2M | $223.8M | $204.2M | $38.9M | $5.4M | −$6.8M |
| Invested capital | −$616.5M | $36.6M | $49.2M | $59.3M | $26.8M | $18.0M | $1.2M | −$3.2M |
| Tangible asset value | −$164.3M | $96.7M | $150.7M | $250.6M | $216.3M | $48.3M | $7.6M | −$6.8M |
| Net current asset value | −$170.3M | $50.3M | $81.7M | $188.2M | $188.1M | $21.5M | $5.4M | −$6.8M |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | $1.2M | $0 | $0 | — | — | — |
| Capex / depreciation | 0.33 | 0.06 | 0.31 | 3.35 | 2.72 | 6.88 | 8.22 | 37.40 |
| Efficiency | ||||||||
| Days payables outstanding | — | 120.0 | 135.2 | 67.6 | 160.2 | 401.8 | 1,466.0 | 693.5 |
| Payables turnover | — | 3.04 | 2.70 | 5.40 | 2.28 | 0.91 | 0.25 | 0.53 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $3.3M | $1.2M | $1.3M | $1.7M | $2.0M | $1.5M | $365,500 | $38,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VOR's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VOR valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.1. It ended the year with $3.0 million of debt and $455.2 million in cash and short-term investments, a net cash position of $452.2 million.
See the VOR income statement, the VOR chart for price history, or the VOR stock overview for the latest quote and news.
VOR key metrics FAQ
What is Vor Biopharma's P/E ratio?
Vor Biopharma's trailing P/E ratio is 0.1 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
How much debt does Vor Biopharma have?
Vor Biopharma had total debt of $3.0 million at the end of fiscal 2025 and more cash than debt.
What is Vor Biopharma's current ratio?
Vor Biopharma's current ratio was 18.20 at the end of fiscal 2025: current assets were 18.20 times current liabilities.